Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
compound herba lysimachiae granules
- Development stage
- Unknown
- Lead developer
- Shanghai Ninth People's Hospital
- Administration
- Oral
01
Overview
Compound Herba Lysimachiae Granules (also known as Fufang Jinqiancao Keli) is a traditional Chinese medicine (TCM) formulation primarily used for the treatment and prevention of urolithiasis, including kidney and ureteral stones. The preparation is a combination of several botanical extracts, with *Lysimachia christinae* Hance (Jin Qian Cao) as the primary active component, supplemented by *Plantago asiatica*, *Imperata cylindrica*, and *Zea mays*. It is pharmacologically characterized by its diuretic, litholytic, anti-inflammatory, and antispasmodic activities. The drug works by increasing urine output, promoting the dissolution and expulsion of stones, and reducing the formation of calcium oxalate crystals. It is currently being evaluated in Phase 4 clinical trials to assess its efficacy in preventing the postoperative recurrence of renal and ureteral stones.
- Brand names
- Fufang Jinqiancao Keli
- Other names
- Compound Lysimachia christinae Hance GranulesCompound Herba Lysimachiae Granules
Beyond the preview
Go deeper on compound herba lysimachiae granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on compound herba lysimachiae granules.